NCT00913666View on ClinicalTrials.gov

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

November 30, 2004

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon beta-1a (Avonex)

30 mcg by intramuscular injection once a week

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00913666 - Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers | Biotech Hunter | Biotech Hunter